395 related articles for article (PubMed ID: 21799367)
21. The Diagnostic Value of 18F-FDG PET/CT Scan in Characterizing Adrenal Tumors.
Schaafsma M; Berends AMA; Links TP; Brouwers AH; Kerstens MN
J Clin Endocrinol Metab; 2023 Aug; 108(9):2435-2445. PubMed ID: 36948598
[TBL] [Abstract][Full Text] [Related]
22. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases.
Chua S; Gnanasegaran G; Cook GJ
Semin Nucl Med; 2009 Nov; 39(6):416-30. PubMed ID: 19801221
[TBL] [Abstract][Full Text] [Related]
23. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract][Full Text] [Related]
24. Role of positron emission tomography in thyroid and neuroendocrine tumors.
Treglia G; Kroiss AS; Piccardo A; Lococo F; Santhanam P; Imperiale A
Minerva Endocrinol; 2018 Sep; 43(3):341-355. PubMed ID: 28949122
[TBL] [Abstract][Full Text] [Related]
25. Adrenal findings in FDG-PET: analysis of a cohort of 1021 patients from a cancer center.
Maciel J; Cavaco D; Fraga D; Donato S; Simões H; Sousa R; Simões-Pereira J
Hormones (Athens); 2023 Mar; 22(1):131-138. PubMed ID: 36477790
[TBL] [Abstract][Full Text] [Related]
26. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
[TBL] [Abstract][Full Text] [Related]
27. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
[TBL] [Abstract][Full Text] [Related]
28. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors.
Bombardieri E; Seregni E; Villano C; Chiti A; Bajetta E
Q J Nucl Med Mol Imaging; 2004 Jun; 48(2):150-63. PubMed ID: 15243410
[TBL] [Abstract][Full Text] [Related]
29. Appropriate use of positron emission tomography with [(18)F]fluorodeoxyglucose for staging of oncology patients.
Tagliabue L; Del Sole A
Eur J Intern Med; 2014 Jan; 25(1):6-11. PubMed ID: 23910561
[TBL] [Abstract][Full Text] [Related]
30. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
31. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH
Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190
[TBL] [Abstract][Full Text] [Related]
32. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients.
Boland GW; Blake MA; Holalkere NS; Hahn PF
AJR Am J Roentgenol; 2009 Apr; 192(4):956-62. PubMed ID: 19304700
[TBL] [Abstract][Full Text] [Related]
33. Clinical applications and advances of positron emission tomography with fluorine-18-fluorodeoxyglucose (18F-FDG) in the diagnosis of liver neoplasms.
He YX; Guo QY
Postgrad Med J; 2008 May; 84(991):246-51. PubMed ID: 18508981
[TBL] [Abstract][Full Text] [Related]
34. (18)F-FDG PET/CT in bilateral primary adrenal T-cell lymphoma.
Santhosh S; Mittal BR; Shankar P; Kashyap R; Bhattacharya A; Singh B; Das A; Bhansali A
Hell J Nucl Med; 2011; 14(2):166-7. PubMed ID: 21761021
[TBL] [Abstract][Full Text] [Related]
35. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
[TBL] [Abstract][Full Text] [Related]
36. Comparison of delayed enhanced CT and 18F-FDG PET/CT in the evaluation of adrenal masses in oncology patients.
Park BK; Kim CK; Kim B; Choi JY
J Comput Assist Tomogr; 2007; 31(4):550-6. PubMed ID: 17882030
[TBL] [Abstract][Full Text] [Related]
37. False positive 18F-FDG PET scan in adrenal oncocytoma.
Acar C; Akkas BE; Sen I; Sozen S; Kitapci MT
Urol Int; 2008; 80(4):444-7. PubMed ID: 18587259
[TBL] [Abstract][Full Text] [Related]
38. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
Menda Y; Graham MM
Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
[TBL] [Abstract][Full Text] [Related]
39. (18)F-FDG PET/CT of adrenal lesions.
Dong A; Cui Y; Wang Y; Zuo C; Bai Y
AJR Am J Roentgenol; 2014 Aug; 203(2):245-52. PubMed ID: 25055255
[TBL] [Abstract][Full Text] [Related]
40. 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.
Minn H; Kemppainen J; Kauhanen S; Forsback S; Seppänen M
PET Clin; 2014 Jan; 9(1):27-36. PubMed ID: 25029931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
